GT Biopharma, Inc. (GTBP)
NASDAQ: GTBP · Real-Time Price · USD
2.940
-0.070 (-2.33%)
At close: Oct 31, 2024, 4:00 PM
2.820
-0.120 (-4.08%)
After-hours: Oct 31, 2024, 6:13 PM EDT

GT Biopharma Stock Forecast

Stock Price Forecast

There is currently no analyst price target forecast available for GT Biopharma.

Analyst Consensus: n/a
Target Low Average Median High
Price n/a n/a n/a n/a
Change n/a n/a n/a n/a

Analyst Ratings

There are currently no analyst ratings available for GT Biopharma.

Recommendation Trends

Rating Mar '23Apr '23May '23Jun '23Jul '23Aug '23
Strong Buy 111110
Buy 000000
Hold 111110
Sell 000000
Strong Sell 000000
Total 222220

Latest Forecasts

Analyst Firm Rating Rating Action Price Target Upside Date
HC Wainwright & Co.
HC Wainwright & Co.
Strong Buy
Reiterates
$150
Strong Buy Reiterates $150 +5,002.04% Aug 8, 2023
EF Hutton
EF Hutton
Hold
Reiterates
$60
Hold Reiterates $60 +1,940.82% Aug 7, 2023
HC Wainwright & Co.
HC Wainwright & Co.
Strong Buy
Reiterates
$150
Strong Buy Reiterates $150 +5,002.04% Jun 5, 2023
HC Wainwright & Co.
HC Wainwright & Co.
Strong Buy
Reiterates
$150
Strong Buy Reiterates $150 +5,002.04% May 17, 2023
EF Hutton
EF Hutton
Hold
Reiterates
$60
Hold Reiterates $60 +1,940.82% May 16, 2023
More Analyst Ratings

Financial Forecast

Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-11.02
from -5.64
EPS Next Year
-0.72
from -11.02
Fiscal Year FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025
Period Ending Dec 31, 2019 Dec 31, 2020 Dec 31, 2021 Dec 31, 2022 Dec 31, 2023 Dec 31, 2024 Dec 31, 2025
Revenue
-------
Revenue Growth
-------
EPS
-342.62-193.58-61.81-19.66-5.64-11.02-0.72
EPS Growth
-------
Forward PE
-------
No. Analysts -----33
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue 20242025
High n/a n/a
Avg n/a n/a
Low n/a n/a

Revenue Growth

Revenue Growth 20242025
High - -
Avg - -
Low - -

EPS Forecast

EPS 20242025
High -11.34 -0.75
Avg -11.02 -0.72
Low -10.58 -0.70

EPS Growth

EPS Growth 20242025
High - -
Avg - -
Low - -
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.